Due to rising importance, impact, volume and quality, Oncotarget will begin publishing two issues per week on Tuesday and Friday.
To accelerate the dissemination of highly important scientific information, all accepted papers will be included directly to final paginated issues to be released to PubMed quickly and in their permanent form.
The entire Volume 8 is now in PubMed.
Issues 9(1-4) are now in PubMed. Please see the link.
Issues 9(5-8) are currently submitting and processing by the National Library of Medicine to appear in PubMed.

New Impact factor (IF) is 5.168

Title IF
e-Life 7.725
Oncogene 7.519
Oncotarget 5.168
Mol Cell Biol 4.398
Sci Reports 4.259
JBC 4.125
BMC Cancer 3.288
PLOS ONE 2.806

According to MEDLINE statement on 6/22/2017,
"This journal continues to play a major role in the publication of important basic science research papers. Editorial practices are consistently high. Ethical guidelines are consistently followed. This is an important research journal for the field."

Featured articles by DR Lowy, the acting director of the NCI (2015-2017):
DLC1 is the principal biologically-relevant down-regulated DLC family member in several cancers. Wang D, Qian X, Rajaram M, Durkin ME, Lowy DR.
Oncotarget. 2016 Jul 19;7(29):45144-45157.
DLC1: a tumor suppressor that regulates Rho signaling. Tripathi BK, Lowy DR.
Oncotarget. 2017 Apr 25;8(17):27674-27675.

Impact factor (IF) Web of Science (Clarivate Analytics)

Year IF Total Cites
2016 5.168 30241
2015 5.008 10452
2014 6.359 3908
2013 6.627 2217
2012 6.636 1450
2011 4.784 493

In October of 2017, Clarivate Analytics, (owner of the Web of Science index) honored Oncotarget as one of the 14 “rising star” journals for 2017.

We remain perplexed by the abrupt decision to not include Oncotarget into the master list of the journals for 2018 without advanced notice and clear grounds. We are actively working to understand and rectify the situation.

The term "Oncotarget" encompasses all molecules, pathways, and cellular functions common in cancer and aging, neurodegeneration and atherosclerosis, lymphocytes and neurons, cancer cells and microbes.

2015/2016: 5-Year Impact Factor: 5.415

Scopus/SJR ranking: 2011-ongoing: Q1 (highest rank). All years Q1 in Medicine and Oncology (subject area).

Oncotarget ranks number 1 on Total Documents (2015-2016) among all journals in Oncology, see here

If your paper was mistakenly rejected by other leading journals, you may submit it to Oncotarget together with peer-reviews obtained from the other journal and rebuttal letter.

Oncotarget is an outstanding and most important journal in the field of oncology and cancer research. Oncotarget is performing an extremely useful function for those of us working not only in cancer research, but also on other important topics in the field of medicine. Oncotarget deserves a strong support from investigators working in the area of oncology as well as from NIH.

-- Andrew V. Schally, member of the Editorial Board
Nobel Prize in Physiology or Medicine, 1977

Members of Editorial Board Carlo M. Croce (former Editor-in-Chief of Cancer Research) and Andrew Schally (Nobel Prize winner) have published 27 and 10 papers in Oncotarget

250 Plus Papers from the Editorial Board:
See full list

Copyright © 2018 Impact Journals
Impact Journals is a registered trademark of Impact Journals, LLC